Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Debt: 2018-2023

Historic Non-Current Debt for Autolus Therapeutics (AUTL) over the last 2 years, with Sep 2022 value amounting to $342.9 million.

  • Autolus Therapeutics' Non-Current Debt rose 24.35% to $342.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $342.9 million, marking a year-over-year increase of 24.35%. This contributed to the annual value of $275.2 million for FY2021, which is N/A change from last year.
  • Latest data reveals that Autolus Therapeutics reported Non-Current Debt of $295,000 as of Q3 2023, which was up 141.80% from $122,000 recorded in Q2 2023.
  • Autolus Therapeutics' Non-Current Debt's 5-year high stood at $295,000 during Q3 2023, with a 5-year trough of $30,000 in Q3 2019.
  • In the last 3 years, Autolus Therapeutics' Non-Current Debt had a median value of $119,000 in 2022 and averaged $139,875.
  • The largest annual percentage gain for Autolus Therapeutics' Non-Current Debt in the last 5 years was 31.05% (2022), contrasted with its biggest fall of 2.69% (2022).
  • Over the past 2 years, Autolus Therapeutics' Non-Current Debt (Quarterly) stood at $269.6 million in 2021, then rose by 24.35% to $342.9 million in 2022.
  • Its Non-Current Debt was $342.9 million in Q3 2022, compared to $366.3 million in Q2 2022 and $268.4 million in Q1 2022.